Roche takes on Loxo, Bayer in gene-defined cancer class

Roche’s entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

Leave a Reply

Read the original at Reuters: Science News.